Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Postepy Biochemii|April 15, 2017
[Watching dance of the molecules - CARS microscopy]Jaroslaw Korczyński, Katarzyna Kubiak, Edyta WęgłowskaCurrent Topics in Medicinal Chemistry|June 20, 2015
Proangiogenic properties of nucleoside 5'-O-phosphorothioate analogues under hyperglycaemic conditionsEdyta Węgłowska, Marcin Szustak, Edyta Gendaszewska-DarmachOncotarget|October 13, 2016
Nucleoside 5'-O-monophosphorothioates as modulators of the P2Y14 receptor and mast cell degranulationEdyta Gendaszewska-Darmach, Edyta Węgłowska, Aurelia Walczak-Drzewiecka, et al.International Journal of Molecular Sciences|January 11, 2022
Extracellular Nucleotides Affect the Proangiogenic Behavior of Fibroblasts, Keratinocytes, and Endothelial CellsEdyta Węgłowska, Maria Koziołkiewicz, Daria Kamińska, et al.Journal of Clinical Medicine|January 11, 2022
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with BortezomibDamian Mikulski, Paweł Robak, Ewelina Perdas, et al.Mediators of Inflammation|June 27, 2020
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with BortezomibPaweł Robak, Edyta Węgłowska, Izabela Dróżdż, et al.Cancers|March 6, 2021
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with BortezomibPawel Robak, Dariusz Jarych, Damian Mikulski, et al.Cancers|September 12, 2020
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma PatientsPaweł Robak, Izabela Dróżdż, Dariusz Jarych, et al.Pageof 1